- Home
- IAE vs LONA Comparison
IAE vs LONA Comparison
Compare IAE & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | LONA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 81.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IAE | LONA |
|---|---|---|
| Price | $8.66 | $7.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 65.8K | 28.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $4.21 |
| 52 Week High | $9.27 | $14.21 |
Technical Indicators
Market Signals| Indicator | IAE | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 48.64 |
| Support Level | $8.43 | $6.86 |
| Resistance Level | $8.68 | $9.78 |
| Average True Range (ATR) | 0.19 | 0.45 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 65.22 | 85.16 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.